BiotechTube

ASP0819 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Mar 20, 2017 → Feb 27, 2018

NCT ID
NCT03056690

About ASP0819 + Placebo

ASP0819 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT03056690. Target conditions include Fibromyalgia.

What happened to similar drugs?

11 of 20 similar drugs in Fibromyalgia were approved

Approved (11) Terminated (3) Active (9)
✅zonisamideEisaiApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + placeboEli LillyApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + placeboSumitomo PharmaApproved
✅QuetiapineAstraZenecaApproved
✅amitriptyline + quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03056690Phase 2Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
DS-5565 + PlaceboDaiichi SankyoPhase 3
40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
ASP8062 + PlaceboAstellas PharmaPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine 60 mg + PlaceboShionogiPhase 3
40
zonisamideEisaiApproved
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
42
DuloxetineEli LillyApproved
35
duloxetine hydrochloride + placeboEli LillyApproved
43
duloxetineEli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
Treatment for FibromyalgiaEli LillyPre-clinical
26
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
Eszopiclone + placeboSumitomo PharmaApproved
43